Hikma Pharmaceuticals (HIK) News Today GBX 2,088 +4.00 (+0.19%) As of 12:06 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Hikma Pharmaceuticals (LON:HIK) Stock Passes Above 200 Day Moving Average - Here's What HappenedHikma Pharmaceuticals (LON:HIK) Share Price Crosses Above Two Hundred Day Moving Average - Time to Sell?January 18 at 4:59 AM | marketbeat.comHikma Pharmaceuticals (LON:HIK) Share Price Crosses Above 200-Day Moving Average - Time to Sell?Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?January 18 at 4:59 AM | marketbeat.comEmergent BioSolutions gains exclusive commercial rights to KLOXXADOJanuary 14, 2025 | msn.comEBS obtains rights to Hikma's Kloxxado naloxone sprayJanuary 14, 2025 | msn.comHikma Pharma Inks Exclusive Commercial Deal With Emergent BioSolutions For KLOXXADO Nasal Spray 8 MgJanuary 14, 2025 | markets.businessinsider.comHikma Pharmaceuticals (LON:HIK) Stock Passes Above Two Hundred Day Moving Average - Time to Sell?Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above Two Hundred Day Moving Average - Here's What HappenedJanuary 10, 2025 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Stock Price Passes Above 200-Day Moving Average - Here's WhyHikma Pharmaceuticals (LON:HIK) Shares Pass Above 200 Day Moving Average - Here's WhyJanuary 10, 2025 | marketbeat.comFDA Announcement: The First Generic GLP-1 Shot Has Just Been ApprovedJanuary 2, 2025 | msn.comHikma Pharmaceuticals (LON:HIK) Share Price Crosses Above 200 Day Moving Average - Here's WhyHikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?January 2, 2025 | marketbeat.comFDA Approves First Generic Liraglutide Injection, Ushering in a New Era for Type 2 Diabetes TreatmentDecember 30, 2024 | msn.comIs Hikma Pharmaceuticals PLC (HIK.L) Among the U.K. Dividend Aristocrats for 2024?December 29, 2024 | msn.comFDA approves Hikma’s generic version of Novo’s diabetes drug VictozaDecember 25, 2024 | msn.comHikma Pharmaceuticals (LON:HIK) Share Price Passes Above 200-Day Moving Average - What's Next?Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above 200 Day Moving Average - What's Next?December 25, 2024 | marketbeat.comFDA approves generic in same class as Ozempic for diabetes. Could it ease shortage, price?December 23, 2024 | yahoo.comThere’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is comingDecember 23, 2024 | msn.comUS FDA revokes authorization for four COVID treatmentsDecember 23, 2024 | reuters.comUS FDA approves Hikma's generic version of Novo's diabetes drug VictozaDecember 23, 2024 | reuters.comHikma Pharmaceuticals (LON:HIK) Stock Passes Above 200-Day Moving Average - What's Next?Hikma Pharmaceuticals (LON:HIK) Shares Cross Above Two Hundred Day Moving Average - What's Next?December 17, 2024 | marketbeat.comBTIG Downgrades Carisma Therapeutics (CARM)December 11, 2024 | msn.comHikma Pharmaceuticals (LON:HIK) Stock Price Down 0.5% - Here's WhyHikma Pharmaceuticals (LON:HIK) Stock Price Down 0.5% - Should You Sell?December 7, 2024 | marketbeat.comHikma Pharmaceuticals rises Monday, still underperforms marketNovember 12, 2024 | marketwatch.comEuropean Stocks Close Lower As Markets Assess Rate Moves, EarningsNovember 9, 2024 | markets.businessinsider.comEuropean Stocks Close Lower As Investors React To Earnings, BoE Rate DecisionNovember 8, 2024 | markets.businessinsider.comHikma Pharmaceuticals reiterates full-year guidance amid strong growthNovember 7, 2024 | lse.co.ukEuropean Stocks Fail To Hold Early Gains, Close WeakNovember 6, 2024 | markets.businessinsider.comUnited Kingdom shares lower at close of trade; Investing.com United Kingdom 100 down 0.17%November 5, 2024 | msn.comHikma Pharmaceuticals (LON:HIK) Shares Pass Above 200 Day Moving Average - What's Next?Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?October 30, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?Hikma Pharmaceuticals (LON:HIK) Share Price Crosses Above Two Hundred Day Moving Average - What's Next?October 22, 2024 | marketbeat.com2024 Research Report | Antipsychotic Drugs Market Poised for Significant Growth by 2030, Advances in Mental Health Treatment Drive DemandOctober 14, 2024 | uk.finance.yahoo.comMajor European Markets Close On Firm NoteOctober 14, 2024 | markets.businessinsider.comGlobal Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsightOctober 10, 2024 | finance.yahoo.comUK stocks swing into the red as oil prices retreatOctober 8, 2024 | msn.comEuropean Stocks Close Lower On Growth Worries As Markets Await Fresh DataOctober 8, 2024 | markets.businessinsider.comEuropean markets finish lower as car manufacturers struggleSeptember 30, 2024 | msn.comU.K. stocks lower at close of trade; Investing.com United Kingdom 100 down 1.05%September 30, 2024 | msn.comHikma Pharmaceuticals PLC (LON:HIK) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buySeptember 26, 2024 | marketbeat.comWith 55% ownership, Hikma Pharmaceuticals PLC (LON:HIK) boasts of strong institutional backingSeptember 25, 2024 | finance.yahoo.comHikma Pharmaceuticals (LON:HIK) Stock Price Passes Above Two Hundred Day Moving Average of $1,917.24Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above 200 Day Moving Average of $1,917.24September 21, 2024 | marketbeat.comGlobal stocks rise as investors hopeful of US interest rate cutSeptember 18, 2024 | msn.comUnited Kingdom shares higher at close of trade; Investing.com United Kingdom 100 up 0.37%September 17, 2024 | msn.comHikma Pharmaceuticals (LON:HIK) Sets New 12-Month Low at $559.00Hikma Pharmaceuticals (LON:HIK) Sets New 52-Week Low at $559.00September 13, 2024 | marketbeat.comUS Allows ADHD Drugmaker To Increase Production Limit To Ease Ongoing ShortageSeptember 6, 2024 | msn.comHikma Pharmaceuticals (LON:HIK) shareholders have endured a 17% loss from investing in the stock three years agoSeptember 4, 2024 | finance.yahoo.comHikma Pharmaceuticals falls Tuesday, still outperforms marketSeptember 3, 2024 | marketwatch.comLONDON BROKER RATINGS: Berenberg raises Hikma Pharmaceuticals to 'buy'September 3, 2024 | lse.co.ukHikma Pharmaceuticals (LON:HIK) Stock Crosses Above 200-Day Moving Average of $1,921.05Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above Two Hundred Day Moving Average of $1,921.05August 29, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Stock Price Passes Above Two Hundred Day Moving Average of $1,917.25Hikma Pharmaceuticals (LON:HIK) Stock Crosses Above 200-Day Moving Average of $1,917.25August 21, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) PT Raised to GBX 2,100Berenberg Bank raised their target price on shares of Hikma Pharmaceuticals from GBX 2,000 ($25.54) to GBX 2,100 ($26.81) and gave the stock a "hold" rating in a report on Monday.August 13, 2024 | marketbeat.comFTSE outperforms European peers after oil prices riseAugust 12, 2024 | msn.comFTSE 100 Rises Ahead Of Key Economic DataAugust 12, 2024 | markets.businessinsider.com Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address HIK Media Mentions By Week HIK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HIK News Sentiment▼0.430.57▲Average Medical News Sentiment HIK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HIK Articles This Week▼52▲HIK Articles Average Week Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HUTCHMED News Indivior News Allergy Therapeutics News Alliance Pharma News Beximco Pharmaceuticals News Animalcare Group News Venture Life Group News ECO Animal Health Group News Shield Therapeutics News Chill Brands Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:HIK) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
